Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Identifieur interne : 000E30 ( Main/Exploration ); précédent : 000E29; suivant : 000E31Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Auteurs : P. Hadji [Allemagne] ; M. Ziller ; D. G. Kieback ; W. Dornoff ; H. W. Tessen [Allemagne] ; T. Menschik [France] ; J. Kuck [Allemagne] ; F. Melchert ; A. Hasenburg [Allemagne]Source :
- Annals of Oncology [ 0923-7534 ] ; 2009-02-13.
Descripteurs français
- Pascal (Inist)
- Wicri :
- geographic : Allemagne.
- topic : Prospective.
English descriptors
- KwdEn :
Abstract
Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P0.0026 and P0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P 0.0009 and P0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.
Url:
DOI: 10.1093/annonc/mdn762
Affiliations:
- Allemagne, France
- Bade-Wurtemberg, Berlin, District de Fribourg-en-Brisgau, Île-de-France
- Berlin, Fribourg-en-Brisgau, Paris
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B53
- to stream Istex, to step Curation: 001A36
- to stream Istex, to step Checkpoint: 000377
- to stream Main, to step Merge: 000F04
- to stream PascalFrancis, to step Corpus: 000674
- to stream PascalFrancis, to step Curation: 000732
- to stream PascalFrancis, to step Checkpoint: 000529
- to stream Main, to step Merge: 001085
- to stream Main, to step Curation: 000E30
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</title>
<author><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name>
</author>
<author><name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name>
</author>
<author><name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name>
</author>
<author><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name>
</author>
<author><name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name>
</author>
<author><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name>
</author>
<author><name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name>
</author>
<author><name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name>
</author>
<author><name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:18C4680D33EFE385185847F4B93A7102B6E899C4</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1093/annonc/mdn762</idno>
<idno type="url">https://api.istex.fr/document/18C4680D33EFE385185847F4B93A7102B6E899C4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001B53</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B53</idno>
<idno type="wicri:Area/Istex/Curation">001A36</idno>
<idno type="wicri:Area/Istex/Checkpoint">000377</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000377</idno>
<idno type="wicri:doubleKey">0923-7534:2009:Hadji P:effects:of:exemestane</idno>
<idno type="wicri:Area/Main/Merge">000F04</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0309205</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000674</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000732</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000529</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000529</idno>
<idno type="wicri:doubleKey">0923-7534:2009:Hadji P:effects:of:exemestane</idno>
<idno type="wicri:Area/Main/Merge">001085</idno>
<idno type="wicri:Area/Main/Curation">000E30</idno>
<idno type="wicri:Area/Main/Exploration">000E30</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</title>
<author><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name>
<affiliation></affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name>
<affiliation><wicri:noCountry code="subField">Marburg</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name>
<affiliation><wicri:noCountry code="subField">Aue</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name>
<affiliation><wicri:noCountry code="subField">Trier</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Onkologische Schwerpunktpraxis, Goslar</wicri:regionArea>
<wicri:noRegion>Goslar</wicri:noRegion>
<wicri:noRegion>Goslar</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Pfizer, Specialty Brand Team Europe, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name>
<affiliation wicri:level="3"><country>Allemagne</country>
<placeName><settlement type="city">Berlin</settlement>
<region type="land" nuts="2">Berlin</region>
</placeName>
<wicri:orgArea>Independent Clinical Research Consulting, Blschestrasse</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name>
<affiliation><wicri:noCountry code="subField">Mannheim</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Freiburg University, Frauenklinik, Freiburg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Fribourg-en-Brisgau</region>
<settlement type="city">Fribourg-en-Brisgau</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Oncology</title>
<idno type="ISSN">0923-7534</idno>
<idno type="eISSN">1569-8041</idno>
<imprint><publisher>Oxford University Press</publisher>
<date type="published" when="2009-02-13">2009-02-13</date>
<biblScope unit="volume">20</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="1203">1203</biblScope>
<biblScope unit="page" to="1209">1209</biblScope>
</imprint>
<idno type="ISSN">0923-7534</idno>
</series>
<idno type="istex">18C4680D33EFE385185847F4B93A7102B6E899C4</idno>
<idno type="DOI">10.1093/annonc/mdn762</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Aromatase inhibitor</term>
<term>Bone</term>
<term>Bone mineral density</term>
<term>Breast cancer</term>
<term>Clinical trial</term>
<term>Early</term>
<term>Exemestane</term>
<term>Fracture</term>
<term>Germany</term>
<term>Health</term>
<term>Osteoporosis</term>
<term>Prospective</term>
<term>Randomization</term>
<term>Tamoxifene</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Allemagne</term>
<term>Anticancéreux</term>
<term>Cancer du sein</term>
<term>Densité minérale osseuse</term>
<term>Essai clinique</term>
<term>Exémestane</term>
<term>Fracture</term>
<term>Inhibiteur de l'aromatase</term>
<term>Os</term>
<term>Ostéoporose</term>
<term>Prospective</term>
<term>Précoce</term>
<term>Randomisation</term>
<term>Santé</term>
<term>Tamoxifène</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Prospective</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P0.0026 and P0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P 0.0009 and P0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>France</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>Berlin</li>
<li>District de Fribourg-en-Brisgau</li>
<li>Île-de-France</li>
</region>
<settlement><li>Berlin</li>
<li>Fribourg-en-Brisgau</li>
<li>Paris</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name>
<name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name>
<name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name>
<name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name>
</noCountry>
<country name="Allemagne"><noRegion><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name>
</noRegion>
<name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name>
<name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name>
<name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E30 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E30 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Rhénanie |area= UnivTrevesV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:18C4680D33EFE385185847F4B93A7102B6E899C4 |texte= Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy }}
![]() | This area was generated with Dilib version V0.6.31. | ![]() |